A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients With Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment With Adalimumab and MTX

Descripción detallada

The maximum study duration per participant enrolled in the open label run-in phase and was eligible to enroll in the randomized phase of main study was 54 weeks: * open label screening period of up to 4 weeks * open-label treatment period of 16 weeks * randomized screening period of 2 to 4 weeks * randomized treatment post-treatment safety follow-up period of 6 weeks. The maximum study duration per participant enrolled only in the open label run-in phase and was not eligible to enroll in the randomized phase of main study was 26 weeks: * open label screening period of up to 4 weeks * open-label treatment period of 16 weeks * open label treatment post-treatment safety follow-up period of 6 weeks. The maximum study duration per participant enrolled in the open label run-in phase and was eligible to enroll in the sarilumab sub-study was 82 weeks: * open label screening period of up to 4 weeks * open-label treatment period of 16 weeks * screening period of 2 to 4 weeks * sarilumab treatment period of 52 weeks * sub-study post-treatment safety follow-up period of 6 weeks.